1. GRAIL will announce Q4 2024 financial results on Feb. 20, 2025. 2. A conference call will discuss results and business progress post-announcement. 3. GRAIL aims to detect cancer early using advanced technology and machine learning. 4. Focused on alleviating the global burden of cancer through innovative detection methods.
Preparations for the earnings announcement often generate investor interest. Positive growth trends in cancer detection can enhance market confidence.
Earnings reports are critical for assessing company performance and market position. GRAIL's mission aligns with healthcare trends, potentially influencing investment decisions.
The upcoming earnings report may create immediate volatility. Historical trends show earnings results prompt short-term price movements.
MENLO PARK, Calif., Feb. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the fourth quarter 2024 following the close of market on Thursday, Feb. 20, 2025. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress.
A link to the live webcast and recorded replay will be available at the investor relations section of GRAIL's website at investors.grail.com.
Please register for the live event at this link.
To ensure timely connection, please register for the teleconference and join the webcast at least ten minutes before the scheduled start of the call. The live webcast and recorded replay are open to all interested parties.
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. For more information, visit grail.com.
SOURCE GRAIL, Inc.